PubMed · 5926133
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
1966-12-31. Niridazole.. https://pubmed.ncbi.nlm.nih.gov/5926133/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
Human protozoal infections are ubiquitous and occur worldwide. In many cases, antiprotozoal agents currently in use predate the modern antibiotic era. Despite the relative lag in development of new antiprotozoal agents, the 1990s have witnessed an increasing level of interest in these infections, inspired by international travel and immigration, a growing awareness of antiprotozoal drug resistance, and the significance of acute and recrudescent protozoal infections in immunosuppressed hosts. This review summarizes for nonclinician readers the past, present, and future therapies for common human protozoal infections, as well as pharmacologic mechanisms of action and resistance and common toxicities associated with these agents.
Parasitic infection due to Giardia lamblia can produce severe, disabling gastrointestinal symptoms. Outbreaks have been linked to contaminated municipal water supplies and situations involving person-to-person contact. Immunocompromised patients are especially at risk. Because microscopic examination of stool detects the parasite in only about half of infected patients, use of enzyme-linked immunosorbent assay to detect Giardia-specific antigen is becoming increasingly popular. In most patients, therapy with quinacrine (Atabrine) hydrochloride, metronidazole (Flagyl, Protostat), or a combination of the two is effective.